BioCentury | Sep 2, 2020
Management Tracks

Career officials Rebello, Felberbaum to lead FDA’s communications

Former FDA commissioners Scott Gottlieb and Robert Califf tweeted their praise Tuesday of the appointment of two long-time FDA officials to head the agency’s communications.  Heidi Rebello will become FDA’s acting associate commissioner for external...
BioCentury | Jul 14, 2020

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

Patient death prompts Cellectis trial halt FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose...
BioCentury | May 9, 2020

Ayala becomes latest to join the year’s bumper crop of biopharma IPOs

Ayala’s public debut late Thursday adds to the more than $4 billion raised from global biopharma IPOs so far this year. This year is outpacing 2019 for total funds raised in IPOs even as investors...
BioCentury | Apr 20, 2020

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

With the first three investments from a new fund launched in partnership with Italian charity Fondazione Telethon to invest in therapies for rare genetic diseases, Sofinnova Partners is aiming to build and expand the country’s...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Jan 23, 2020
Clinical News

Risdiplam hits again in FIREFISH, setting up oral option for SMA patients

As risdiplam inches closer to the market in spinal muscular atrophy, the oral candidate notched another win, hitting the primary endpoint in the Phase II/III FIREFISH study and setting up a new alternative for SMA...
BioCentury | Jan 11, 2020

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
Items per page:
1 - 10 of 289